莫西沙星和克拉霉素治疗社区获得性肺炎疗效观察

Study on the Effectiveness of Moxifloxacin and Clarithromycin in Treating Community Acquired Pneumonia

目的:观察莫西沙星治疗社区获得性肺炎(CAP)的效果。方法:采用随机对照的方法,用克拉霉素为对照药,两组各30例,实验组予莫西沙星400mg口服每天一次,对照组予克拉霉素500mg口服每天二次,疗程7～14d。结果:莫西沙星组临床总有效率96.6%,克拉霉素组92.8%,两组细菌清除率分别为100%及92。3%,不良反应发生率分别为6.9%和10.3%。结论:莫西沙星临床疗效,不良反应与克拉霉素相似,是治疗CAP安全、有效的药物。

Objective: To evaluate the moxifloxacin effectiveness in treating community acquired pneumonia. Method: By using of randomized controlled clinical trial.60 patients were randomly assigned to the case group with moxifloxacin and the control group with clarithromycin, both groups were 30 cases, doses of both groups were taken orally 400mg/d qd and 500mg/d bid respectively, the therapy duration was 7～14 days. Result: The total clinical effective rate of both groups were 96.6% and 92.8%respectively,and bacteria eliminating rate were 100% and 92.8% respectively, and the rate of advrerse reaction were 6.9% and 10.3% respectively. Conclusion: There is no significanf difference in the clinical effectiveness and the rate of adverse reaction between two groups, so moxifloxacin is aslo an effective and safe antibacterial drug in treating community acquired pneumonia.